Objective
to compare outcomes of patients treated with bioresorbable vascular scaffolds (BVS) vs everolimus-eluting stents (EES)
Study
active-controlled, blinded, multicentre, randomised trial
Population
patients with stable CAD or ACS aged 18 years or older
Endpoints
target-lesion failure = cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularisation
Conclusion
target lesion failure rates were numerically higher with BVS vs EES at 30 days and 1 year though criteria for non-inferiority were met
Stone et al. Lancet. 2018;392:1530-40
